5000 atomic absorption spectrophotometer with deuterium background correction, an AS-40 autosampler, and an HGA-500 graphite furnace (all from Perkin-Elmer Corp., Norwalk, CT). The spectrophotometer was set in peak height mode, scale expansion 5. Aliquots of 30 L were delivered to the pyrolytically coated graphite tube and each solution was analyzed in triplicate. The graphite-furnace program was as follows: step 1: 90 #{176}C, ramp 10 s, hold 60 s; step 2: 120 #{176}C, ramp 20 s, hold 20 s; step 3: 1000#{176}C, ramp 10 s, hold 30 5; step 4: 2500 #{176}C, ramp 0 s, hold 4 s, recorder and read on, baseline -5 s, internal argon flow 10 mL/min; step 5: 2700 #{176}C, ramp 2 s, hold 3 s; step 6: 20 #{176}C, ramp 2 s, hold 18 s. This work was supported by NIH Grant no. HD-19547 and no.
5R22 AM 12432 and Grant RR-69 from the General Clinical
Research Centers. FCA is used in the treating of Addison's disease, a daily dose of 0.1-0.3 mg producing satisfactory retention of salt. Less commonly the drug is used in the treatment of adrenal hyperplasia, a daily dose of 1-2 mg being used to inhibit endogenous cortisol secretion.
To assess the cross reactivity of FCA in the Corti-Cote assay, we determined what concentration decreased maximum binding in the assay by 50%. This was then related to the concentration of cortisol that decreased binding to the same degree, and the percentage cross reactivity was calculated.
We prepared a range of concentrations of FCA, 3 to 50000 pg/L, from an aqueous 0.1 g/L stock solution obtainedfrom the hospital pharmacy, using the kit's zero standard as diluent. A Corti-Cote assay was then set up in duplicate as per the manufacturer's instructions. The dilutions of FCA were assayed as serum samples and the concentrations of cortisol and FCA that decreased maximum binding by 50% were determined to be 27.5 pg/L for cortisol, 19600 p.g/L for FCA. Thus the cross reactivity of FCA was (27.5/19 600) x 100 = 0.14%. Therefore at the theoretical maximum concentration of FCA achieved with therapeutic dosage, about 40 pg/L, the increase in measured serum cortisol by the CortiCote assay would be 56 ng/L (0.15 nmol/L). In comparing the performance of glucose and urea nitrogen, the Beckman "Astra 8" was used with Beckman reagents (Beckman Instruments Inc., Brea, CA). Other instruments compared with the Reflotron included the "Coulter Counter IV Plus" (Coulter Electronics Inc., Hialeah, FL 33010) for hemoglobin, and the ABA-100 discrete batch analyzer (Abbott Laboratories, Dallas, TX) for cholesterol, triglycerides, and y-glutamyltransferase. Kits supplied by Boehringer-Mannheim Canada were used in method comparison on the ABA-bOO. The range of linearity of
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